Please login to the form below

Not currently logged in
Email:
Password:

Dr Richard Barker joins Celgene's board of directors

Former ABPI director general takes up second new post this month

Richard Barker - CelgeneFormer director general of the Association of the British Pharmaceutical Industry (ABPI) Dr Richard Barker has been elected to the board of directors at Celgene.

He spent almost seven years at ABPI's helm, stepping down in May last year when he was succeeded by Stephen Whitehead.

It is Barker's second recent appointment after he joined authentication and traceability services company Aegate earlier this month as a senior adviser.

Prior to his post leading the ABPI, Barker's career included serving as chief executive of Chiron Diagnostics, general manager of IBM's Worldwide Healthcare Solutions division and leader of McKinsey & Company's European healthcare practice.

Robert Hugin, Celgene's chairman and CEO, said: “As we continue to expand our global reach, Dr Barker's international perspective will enhance our ability to navigate through an increasingly dynamic healthcare landscape and provide patients access to our innovative therapies.”

The US biopharmaceutical company focuses on developing and commercialising novel treatments for cancer and inflammatory diseases.

Its top-selling product is Revlimid, which suffered a setback last November after a phase III prostate cancer trial found no overall survival benefit.

Nevertheless, the drug is still expected to account for around $3bn of the firm's 2011 sales.

24th January 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics